Seeking Alpha

Smith On Stocks'  Instablog

Smith On Stocks
Send Message
Follow @SmithOnStocks on Twitter for more updates (http://twitter.com/#SmithOnStocks Please read this section carefully for some important disclosures. Who Am I? My name is Larry Smith. My career was spent on Wall Street as a biotechnology and pharmaceuticals analyst and also as Director of... More
My company:
SmithOnStocks.com
My blog:
Smith On Stocks
  • Neuralstem: Previewing Potential Key Events For 2014 1 comment
    Jan 8, 2014 11:26 AM | about stocks: CUR

    I have just completed an update on potentially important, stock driving events for Neuralstem (NYSEMKT:CUR) in 2014. The complete report is free to all on my website. The introduction to the report is as follows:

    Neuralstem's clinical trial programs and accompanying results for its two key drugs, the neural stem cell product NSI-566 (its lead drug) and its small molecule drug NSI-189, are picking up a good deal of momentum. This year holds the promise for several events that could continue to drive the stock. The purpose of this report is to highlight potential key events of 2014.

    Results from the clinical trials of NSI-566 in ALS are the most important near term drivers of the stock. I believe that a paper summarizing the complete results of NSI-566 in its phase I trial could be published in a peer reviewed journal by the lead investigator on the trial, Dr. Eva Feldman. She is Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System and an unpaid consultant to Neuralstem. She is also the past President (2013) of the American Neurological Association.

    Because of her credentials and the great interest in this program by the neurological community, this paper could lead to much greater awareness of the promising signals of activity seen in phase I, to the benefit of the stock. In regard to the phase I trial Dr. Feldman has said "Collectively, these preliminary results suggest that intraspinal stem cell transplantation of ALS subjects, with no bulbar symptoms, early in the course of their disease, could slow disease progression and even allow for functional improvement."

    The entire report is about nine pages in length and is available at no charge on my website.

    Disclosure: I am long CUR.

    Stocks: CUR
Back To Smith On Stocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • vireoman
    , contributor
    Comments (1070) | Send Message
     
    Thank you, Mr Smith.
    9 Jan 2014, 10:28 PM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.